Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 120 recruiting now full pipeline #22 of 28,707 conditions

Type 2 Diabetes: full-pipeline trial registry

120 of 328 indexed Type 2 Diabetes trials are currently recruiting.

Corpus placement: #22 of 28,707 conditions by registered trial count.

328 US clinical trials · 120 currently recruiting · #22 of 28,707 conditions by registered trial count

Type 2 Diabetes: 328 US clinical trials tracked, 120 recruiting.

Type 2 Diabetes is the subject of 328 registered US clinical trials on ClinicalTrials.gov, 120 of them currently open to new participants. 60 are in Phase 3-4 (later-stage) and 50 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 20 of these trials.

Enrollment posture brief

Registry condition type-2-diabetes

OPEN 120 | RECR 37% | LATE 60 | EARLY 50 | RANK #22 | SPON 20

Nearest open-share peer: Advanced Cancer (37% recruiting · 123 trials)

Ovarian Cancer43.5%Multiple Sclerosis37.9%Type 2 Diabetes (this)37%Lymphoma26.7%Schizophrenia23.9%
Open-enrollment share among volume-matched conditions near Type 2 Diabetes

Type 2 Diabetes lists 120 open slots (37% of 328 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Type 2 Diabetes on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Type 2 Diabetes recruits in line with its size-band peers.

    120 of 328 indexed trials (36.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Type 2 Diabetes trials is spread across many organizations.

    Eli Lilly and Company accounts for 20 of 328 trials (6.1%). 153 distinct sponsors appear on at least one study for this condition label.

  3. Typical Type 2 Diabetes enrolment sits around 96 participants.

    Median target enrolment is 96 among the 328 trials that report a genuine target (sentinel values excluded). 166 of those (50.6%) plan for fewer than 100 participants.

  4. Type 2 Diabetes research is mostly interventional.

    290 interventional and 38 observational studies make up this index (88.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 125Phase 225Phase 335Phase 425

Open and recent trials

328 total, page 5 of 7

COMPLETED Phase 3 424 participants

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia

Amgen

NCT02739984

COMPLETED Phase 2 396 participants

Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin

Gilead Sciences

NCT00353587

COMPLETED Phase 2 382 participants

An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

Novartis Pharmaceuticals

NCT03060577

COMPLETED Phase 2 356 participants

Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients

Metabolic Solutions Development Company

NCT01103414

COMPLETED Phase 3 353 participants

Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

Mannkind Corporation

NCT01451398

COMPLETED NA 350 participants

Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications

University of Colorado, Denver

NCT05166382

COMPLETED NA 321 participants

Family Model Diabetes Self-Management Education in Faith Based Organizations

University of Arkansas

NCT04256486

COMPLETED Phase 2 318 participants

A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy

Eli Lilly and Company

NCT02973100

COMPLETED Phase 3 315 participants

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

AstraZeneca

NCT01619059

COMPLETED NA 301 participants

Power-Up: An Effectiveness Trial of the Diabetes Prevention Program

Albert Einstein College of Medicine

NCT04104243

COMPLETED Phase 3 300 participants

WelChol® With Metformin in Treating Patients With Type 2 Diabetes

Daiichi Sankyo

NCT00147719

COMPLETED NA 281 participants

Changing Health Through Food Support for Diabetes

University of California, San Francisco

NCT04959487

COMPLETED Phase 2 277 participants

Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)

Joslin Diabetes Center

NCT00392678

COMPLETED Phase 3 268 participants

Diabetes Support Project: Couples Intervention

State University of New York - Upstate Medical University

NCT01017523

COMPLETED NA 240 participants

REMEDIES4D: REdesigning MEDication Intensification Effectiveness Study for Diabetes

University of Pittsburgh

NCT01611168

COMPLETED NA 240 participants

Taking Action Together- A Diabetes Prevention Program

University of California, Berkeley

NCT01039116

COMPLETED Phase 4 239 participants

Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.

AstraZeneca

NCT02288273

COMPLETED NA 227 participants

UCSD Take Charge Study

University of California, San Diego

NCT01345500

COMPLETED Phase 2 227 participants

Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

Biogen

NCT00811889

COMPLETED Phase 3 219 participants

Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg

AstraZeneca

NCT00918138

COMPLETED Phase 2 213 participants

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone

ActivX Biosciences

NCT00525330

COMPLETED 210 participants

Physical Health in Midlife: Influences of Adversity and Relationships Over Time

Beth Israel Deaconess Medical Center

NCT01853332

COMPLETED NA 210 participants

Medically Tailored Groceries and Food Resource Coaching

University of Texas Southwestern Medical Center

NCT06242808

COMPLETED Phase 2 209 participants

Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

Hanmi Pharmaceutical Company Limited

NCT02081118

COMPLETED NA 200 participants

Video Games for Obesity and Diabetes Prevention-Diab & Nano

Baylor College of Medicine

NCT01846377

COMPLETED Phase 3 187 participants

A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

Eli Lilly and Company

NCT04605991

COMPLETED Phase 2 179 participants

A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics

Jiangsu HengRui Medicine Co.

NCT04663282

COMPLETED Phase 3 169 participants

Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin

Daiichi Sankyo

NCT00484419

COMPLETED Phase 3 156 participants

Low Carbohydrate Diet Compared to Calorie and Fat Restricted Diet in Patients With Obesity and Type II Diabetes

US Department of Veterans Affairs

NCT00108459

COMPLETED Phase 4 150 participants

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

Emory University

NCT02455076

COMPLETED NA 150 participants

Pragmatic Impact of Proteomic Risk Stratification in Diabetes Mellitus

University Hospitals Cleveland Medical Center

NCT05182359

COMPLETED NA 140 participants

Program ACTIVE II: Behavioral Depression Treatment for Type 2 Diabetes

Indiana University

NCT03371940

COMPLETED Phase 3 130 participants

Automated Insulin Delivery for Inpatients With Dysglycemia

Emory University

NCT06418880

COMPLETED Phase 1 128 participants

A Safety Study of ARRY-403 in Patients With Type 2 Diabetes

Array Biopharma, now a wholly owned subsidiary of Pfizer

NCT00952198

COMPLETED NA 116 participants

Effect of Aerobic Interval Training on Cardiovascular Function in Type 2 Diabetes

University of Florida

NCT01883258

COMPLETED Phase 4 114 participants

Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

Loyola University

NCT00911625

COMPLETED NA 113 participants

Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men

Pennington Biomedical Research Center

NCT01787617

COMPLETED NA 113 participants

Worksite Nutrition Study

Physicians Committee for Responsible Medicine

NCT00481897

COMPLETED NA 112 participants

Effect of Dairy Consumption on Glycemic Control, Body Weight and Cardiovascular Risk in Patients With Type 2 Diabetes

Joslin Diabetes Center

NCT02895867

COMPLETED NA 111 participants

The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes

Walter Reed National Military Medical Center

NCT01738802

COMPLETED NA 105 participants

Dietary Approaches to Stop Hypertension for Diabetes

Johns Hopkins University

NCT04286555

COMPLETED Phase 4 104 participants

The Health Influences of Puberty (HIP) Study

University of Colorado, Denver

NCT01775813

COMPLETED NA 101 participants

A Study to Assess the Effect of Psyllium vs. Wheat Dextrin on Glycemic Control and Inflammatory Markets in Diabetes Mellitus 2

Mayo Clinic

NCT04547790

COMPLETED NA 100 participants

Randomized Trial to Evaluate the Effectiveness of Nurse Case Management

Johns Hopkins University

NCT00295256

COMPLETED NA 100 participants

Partners in Care Diabetes Self-management Intervention

University of Hawaii

NCT01235429

COMPLETED NA 100 participants

Evaluation of a Digital Diabetes Self-Management Education and Support Program

Omada Health

NCT05368454

COMPLETED 96 participants

Progression and Etiology of Cortical Porosity in Diabetic Bone Disease

University of California, San Francisco

NCT04208230

COMPLETED Phase 1 96 participants

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

Novartis

NCT00567047

COMPLETED Phase 2 94 participants

Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus

CPEX Pharmaceuticals

NCT00850096

COMPLETED NA 92 participants

Vitamin D Supplementation on Cardiovascular Risk Factors

Florida International University

NCT01412710

← Previous Page 5 of 7 Next →

Phase Distribution

PhaseTrial count
Phase 1 25
Phase 2 25
Phase 3 35
Phase 4 25

Named interventions

Most-linked intervention names on Type 2 Diabetes records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
36 trials
Placebo Other
10 trials
Tirzepatide Drug
8 trials
Dapagliflozin Drug
7 trials
Metformin Drug
7 trials
Semaglutide Drug
6 trials
Dulaglutide Drug
5 trials
Saxagliptin Drug
5 trials

US sites by state

Facility locations filed on Type 2 Diabetes trials. A trial with sites in several states counts in each.

California 81 trials
Florida 56 trials
Texas 46 trials
Georgia 38 trials
New York 34 trials
Massachusetts 31 trials
Ohio 30 trials
Illinois 28 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Type 2 Diabetes page

328 registered trials, 120 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Type 2 Diabetes condition card totals 328 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.